Thermadyne Holdings Q2 net sales up 19% YoY, net income increases 132% YoY.

• Thermadyne Holdings Corporation reports Q2 2011 net sales of $129.3mln, a 19% increase. • Net income for Q2 2011 is $6.0mln, a 132% increase. • Adjusted EBITDA for Q2 2011 is $25.8mln, a 70.5% increase. • Net sales for H1 2011 are $245.8mln, a 19.8% increase. • Net income for H1 2011 is $5.9mln, a 21.5% increase. • Adjusted EBITDA for H1 2011 is $43.2mln, a 50.9% increase.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company specializing in gastrointestinal and rare diseases, has reiterated its full-year 2025 financial guidance and raised its adjusted EBITDA forecast. The company announced these updates following strong prescription demand growth for its LINZESS U.S. product in the first quarter of 2025.

Key Financial Highlights:

- LINZESS U.S. Net Sales: Ironwood has maintained its 2025 guidance for LINZESS U.S. net sales, projecting $800-$850 million. This represents a high single-digit growth in prescription demand, which is expected to be offset by price erosion due to Medicare Part D redesign.
- Total Revenue: The total revenue guidance for 2025 remains at $260-$290 million.
- Adjusted EBITDA: The company has raised its adjusted EBITDA guidance to greater than $105 million for 2025. This increase reflects a shift in focus from commercial launch planning investments to the confirmatory Phase 3 trial, in line with recent FDA feedback.

Q1 2025 Performance:

- Prescription Demand: Total LINZESS prescription demand in the first quarter of 2025 was 53 million LINZESS capsules, an 8% increase compared to the first quarter of 2024, per IQVIA.
- Net Sales: LINZESS U.S. net sales were $138.5 million in the first quarter of 2025, a 46% decrease compared to $256.6 million in the first quarter of 2024. This change reflects a refinement in AbbVie’s estimate of gross-to-net rebate reserves.

Impact on Full-Year Results:

Ironwood expects the change in estimate of rebates owed for units dispensed in the first quarter of 2025 to have a negative impact on Q1 2025 net sales but does not anticipate this to affect the full-year results. The company expects rebates owed for units dispensed in subsequent quarters to offset the Q1 2025 change in estimate impact, resulting in no overall impact for the full year.

Conclusion:

The updates from Ironwood Pharmaceuticals indicate continued strong demand for LINZESS, despite challenges related to pricing and rebate reserves. The company’s focus on the confirmatory Phase 3 trial for apraglutide, a next-generation GLP-2 analog, suggests a strategic shift aimed at long-term growth. Investors should closely monitor the company’s progress in the coming quarters.

References:

[1] https://www.businesswire.com/news/home/20250425289111/en/Ironwood-Pharmaceuticals-Reiterates-Full-Year-2025-LINZESS-U.S.-Net-Sales-Guidance-and-Raises-Adjusted-EBITDA-Guidance